Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | TYMS | P04818 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6387841 | 1.00 | CYP19A1 (0.40) | CYP19A1CYP11B1CYP11B2TYMSMEN1 | |
| SCHEMBL6385408 | 0.78 | MAPK14 (0.47) | CYP19A1CYP11B1CYP11B2TYMSMEN1 | |
| SCHEMBL6385244 | 0.76 | MEN1 (0.42) | CYP19A1CYP11B1CYP11B2MEN1KMT2A | |
| SCHEMBL6385247 | 0.76 | MEN1 (0.42) | CYP19A1CYP11B1CYP11B2MEN1KMT2A | |
| SCHEMBL6391836 | 0.75 | CYP11B1 (0.44) | CYP19A1CYP11B1CYP11B2TYMSMEN1 | |
| SCHEMBL6391832 | 0.75 | CYP11B1 (0.44) | CYP19A1CYP11B1CYP11B2TYMSMEN1 | |
| SCHEMBL6387798 | 0.75 | MAPK14 (0.43) | CYP19A1CYP11B1CYP11B2TYMSMEN1 | |
| SCHEMBL6387801 | 0.75 | MAPK14 (0.43) | CYP19A1CYP11B1CYP11B2TYMSMEN1 | |
| SCHEMBL4238327 | 0.71 | TYMS (0.37) | CYP19A1CYP11B1CYP11B2TYMS | |
| SCHEMBL1869865 | 0.70 | MAPK14 (0.43) | CYP19A1CYP11B1CYP11B2TYMSMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245503-A1 | Therapeutic heterocycles | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245503-A1 | Therapeutic heterocycles | OPRK1, RECQL, OPRM1 | CYP19A1 763/4885CYP11B1 500/4885CYP11B2 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.